| Market Cap | 6.8B |
| Market Cap (USD) | $944.5M |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | -0.54 |
| Dividend Yield | - |
| D/E Ratio | 0.59 |
| Current Ratio | 3.10 |
| Market Segment | STAR Market |
| Currency | CNY |
Business Overview
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | C27医药制造业 |
| Market Segment | STAR Market |
| Currency | CNY |
| Fiscal Year | 2024 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | 前沿生物 |
| Ticker | 688221 |
| Exchange | SSE |
| Sector | 证监会行业分类 |
| Industry | C27医药制造业 |
| Market Segment | STAR Market |
| Fiscal Year | 2024 |
| Currency | CNY |
| Market Cap | 6.8B |
| Market Cap (USD) | $944.5M |
| Revenue | 129.0M |
| Net Income | -201.0M |
| P/E Ratio | - |
| EPS | -0.54 |
| Net Margin | -155.8% |
| ROE | -17.6% |
| Dividend Yield | - |
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.